Evidence map›Paper›PMID 33769687›Full record

ArticleJournal of cellular and molecular medicine2021

Priming of mesenchymal stem cells with a hydrosoluble form of curcumin allows keeping their mesenchymal properties for cell-based therapy development.

Margaux Colin, Lola Dechêne, Justine Ceusters, Ariane Niesten, Catherine Demazy, Laurence Lagneaux, Karim Zouaoui Boudjeltia, Thierry Franck, Pierre Van Antwerpen, Patricia Renard and 2 more

Abstract read
In one paragraph

Article in Journal of cellular and molecular medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Margaux ColinDepartment of Pharmacotherapy and Pharmaceuticals, Faculty of Pharmacy, Université libre de Bruxelles (ULB), Brussels, Belgium.
Lola DechêneDepartment of Clinical Sciences, Anaesthesiology and Equine Surgery, Faculty of Veterinary Medicine, B41, University of Liege, Sart Tilman, Liège, Belgium.ORCID 0000-0002-1624-2202
Justine CeustersCentre of Oxygen, Research and Development, Institute of Chemistry B6a, University of Liege (ULiège), Sart Tilman, Liège, Belgium.
Ariane NiestenCentre of Oxygen, Research and Development, Institute of Chemistry B6a, University of Liege (ULiège), Sart Tilman, Liège, Belgium.
Catherine DemazyUnité de Recherche en Biologie Cellulaire (URBC) - Namur Research Institute for Life Sciences (Narilis), University of Namur (UNamur), Namur, Belgium.
Laurence LagneauxLaboratory of Clinical Cell Therapy, ULB-Research Cancer Center (U-CRC), Jules Bordet Institute, Université libre de Bruxelles (ULB), Brussels, Belgium.
Karim Zouaoui BoudjeltiaLaboratory of Experimental Medicine, Université libre de Bruxelles, CHU de Charleroi, Hôpital Vésale, Montigny-le-Tilleul, Belgium.
Thierry FranckCentre of Oxygen, Research and Development, Institute of Chemistry B6a, University of Liege (ULiège), Sart Tilman, Liège, Belgium.
Pierre Van AntwerpenRD3- Pharmacognosy, Bioanalysis and Drug Discovery Unit and Analytical Platform, Faculty of Pharmacy, Université libre de Bruxelles (ULB), Brussels, Belgium.
Patricia RenardUnité de Recherche en Biologie Cellulaire (URBC) - Namur Research Institute for Life Sciences (Narilis), University of Namur (UNamur), Namur, Belgium.
Véronique MathieuDepartment of Pharmacotherapy and Pharmaceuticals, Faculty of Pharmacy, Université libre de Bruxelles (ULB), Brussels, Belgium.
Didier SerteynDepartment of Clinical Sciences, Anaesthesiology and Equine Surgery, Faculty of Veterinary Medicine, B41, University of Liege, Sart Tilman, Liège, Belgium.

Funding

Fondation Universitaire de BelgiqueService Public de Wallonie convention number 1610151Service Public de Wallonie WALInnov program
6 · The paper itself

Abstract

Mesenchymal stem cells are increasingly studied for their use as drug-carrier in addition to their intrinsic potential for regenerative medicine. They could be used to transport molecules with a poor bioavailability such as curcumin in order to improve their clinical usage. This natural polyphenol, well-known for its antioxidant and anti-inflammatory properties, has a poor solubility that limits its clinical potential. For this purpose, the use of NDS27, a curcumin salt complexed with hydroxypropyl-beta-cyclodextrin (HPβCD), displaying an increased solubility in aqueous solution, is preferred. This study aims to evaluate the uptake of NDS27 into skeletal muscle-derived mesenchymal stem cells (mdMSCs) and the effects of such uptake onto their mesenchymal properties. It appeared that the uptake of NDS27 into mdMSCs is concentration-dependent and not time-dependent. The use of a concentration of 7 µmol/L which does not affect the viability and proliferation also allows preservation of their adhesion, invasion and T cell immunomodulatory abilities.

Indexed as

Cell Differentiation2-Hydroxypropyl-beta-cyclodextrinAnimalsAnti-Inflammatory Agents, Non-SteroidalCell- and Tissue-Based TherapyCells, CulturedCurcuminDrug CarriersHorsesMesenchymal Stem CellsMuscle, Skeletal2-Hydroxypropyl-beta-cyclodextrinAnti-Inflammatory Agents, Non-SteroidalCurcuminDrug Carrierscurcumincyclodextrinequine MSCsmdMSCmesenchymal stem cellsmitochondriaNDS27

Identifiers

PMID33769687
PMCPMC8107093

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.